Jung Seungwon, CEO of HanAll Biopharma, received a commendation from the Minister of Trade, Industry and Energy at the "Global Advanced Industry Technology Cooperation Forum 2025," which was held at COEX in Gangnam, Seoul, on December 5. He was highly recognized for introducing global bio-innovation technologies and establishing the foundation to integrate them into the domestic research environment.
The Minister's Award for International Industrial Technology Cooperation is presented to individuals or organizations that have made leading contributions to international cooperation and technology exchange in industrial technology, thereby advancing industrial innovation and enhancing national technological competitiveness.
Jung Seungwon was awarded this honor in recognition of his contributions as the principal investigator of international industrial technology cooperation projects, promoting international technology collaboration and industrial development. The project in question aims to develop treatments for eye and ear diseases using rejuvenation technologies and is being carried out in cooperation with research institutes and companies in the United States.
Notably, Jung Seungwon established a "bidirectional technology cooperation model" that goes beyond simply introducing technology to also foster domestic development capabilities, thereby laying the groundwork for the domestic development of advanced foreign technologies. By dispatching research personnel to the United States, building a real-time collaboration system with domestic research centers, and establishing an integrated joint research environment, he also strengthened the foundation for technology localization by implementing education and advisory systems for researchers.
Since joining HanAll Biopharma in 2020, Jung Seungwon has played a key role in expanding the company's portfolio by turning numerous open collaborations into tangible results. Based on strategic partnerships with global companies such as NurrOn Pharmaceuticals, Turn Biotechnologies, and Vincere Biosciences, he has established an open technology cooperation framework, achieved joint development of Parkinson's disease treatments, and introduced rejuvenation technologies, successfully linking overseas technologies to the research and development stage.
With this award as a stepping stone, HanAll Biopharma plans to further strengthen joint development with global companies, research personnel exchanges, and technology localization systems, thereby continuously enhancing the competitiveness of its current development pipeline.
Jung Seungwon, CEO of HanAll Biopharma, stated, "I will continue to do my best to strengthen the national bio-competitiveness and support the global advancement of domestic companies through open collaboration."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
